Samsung Biologics Co.,Ltd. Statistics

Total Valuation

Samsung Biologics Co.,Ltd. has a market cap or net worth of KRW 73.74 trillion. The enterprise value is 73.85 trillion.

Market Cap	73.74T
Enterprise Value	73.85T

Important Dates

The next estimated earnings date is Thursday, October 24, 2024.

Earnings Date	Oct 24, 2024
Ex-Dividend Date	n/a

Share Statistics

Samsung Biologics Co.,Ltd. has 71.17 million shares outstanding. The number of shares has decreased by -0.01% in one year.

Shares Outstanding	71.17M
Shares Change (YoY)	-0.01%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	14.14%
Float	18.07M

Valuation Ratios

The trailing PE ratio is 71.70 and the forward PE ratio is 65.72.

PE Ratio	71.70
Forward PE	65.72
PS Ratio	17.51
PB Ratio	7.14
P/FCF Ratio	69.29
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 38.95, with an EV/FCF ratio of 69.39.

EV / Earnings	71.81
EV / Sales	17.54
EV / EBITDA	38.95
EV / EBIT	55.78
EV / FCF	69.39

Financial Position

The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.16.

Current Ratio	1.35
Quick Ratio	0.39
Debt / Equity	0.16
Debt / EBITDA	0.89
Debt / FCF	1.58
Interest Coverage	20.26

Financial Efficiency

Return on equity (ROE) is 10.47% and return on invested capital (ROIC) is 6.99%.

Return on Equity (ROE)	10.47%
Return on Assets (ROA)	5.17%
Return on Capital (ROIC)	6.99%
Revenue Per Employee	931.08M
Profits Per Employee	227.37M
Employee Count	4,523
Asset Turnover	0.26
Inventory Turnover	0.80

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +41.05% in the last 52 weeks. The beta is 0.39, so Samsung Biologics Co.,Ltd.'s price volatility has been lower than the market average.

Beta (5Y)	0.39
52-Week Price Change	+41.05%
50-Day Moving Average	970,700.00
200-Day Moving Average	833,760.00
Relative Strength Index (RSI)	56.71
Average Volume (20 Days)	130,388

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Samsung Biologics Co.,Ltd. had revenue of KRW 4.21 trillion and earned 1.03 trillion in profits. Earnings per share was 14,449.16.

Revenue	4.21T
Gross Profit	2.10T
Operating Income	1.32T
Pretax Income	1.38T
Net Income	1.03T
EBITDA	1.90T
EBIT	1.32T
Earnings Per Share (EPS)	14,449.16

Full Income Statement

Balance Sheet

The company has 1.57 trillion in cash and 1.68 trillion in debt, giving a net cash position of -112.96 billion or -1,587.04 per share.

Cash & Cash Equivalents	1.57T
Total Debt	1.68T
Net Cash	-112.96B
Net Cash Per Share	-1,587.04
Equity (Book Value)	10.33T
Book Value Per Share	145,113.73
Working Capital	1.40T

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.65 trillion and capital expenditures -589.36 billion, giving a free cash flow of 1.06 trillion.

Operating Cash Flow	1.65T
Capital Expenditures	-589.36B
Free Cash Flow	1.06T
FCF Per Share	14,952.33

Full Cash Flow Statement

Margins

Gross margin is 49.91%, with operating and profit margins of 31.45% and 24.42%.

Gross Margin	49.91%
Operating Margin	31.45%
Pretax Margin	32.70%
Profit Margin	24.42%
EBITDA Margin	45.03%
EBIT Margin	31.45%
FCF Margin	25.27%

Dividends & Yields

Samsung Biologics Co.,Ltd. does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.01%
Shareholder Yield	0.01%
Earnings Yield	1.39%
FCF Yield	1.44%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Samsung Biologics Co.,Ltd. has an Altman Z-Score of 6.41.

Altman Z-Score	6.41
Piotroski F-Score	n/a